Prescription Drug Advertising to Consumers PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Prescription Drug Advertising to Consumers PDF full book. Access full book title Prescription Drug Advertising to Consumers by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. Download full books in PDF and EPUB format.
Author: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations
Publisher:
ISBN:
Category : Advertising
Languages : en
Pages : 276
Get Book Here
Book Description
Author: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations
Publisher:
ISBN:
Category : Advertising
Languages : en
Pages : 276
Get Book Here
Book Description
Author: United States. Congress. House. Committee on Government Operations. Intergovernmental Relations Subcommittee
Publisher:
ISBN:
Category :
Languages : en
Pages : 30
Get Book Here
Book Description
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Get Book Here
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author: Stephany De Scisciolo
Publisher: Rowman & Littlefield
ISBN: 1498574173
Category : Social Science
Languages : en
Pages : 141
Get Book Here
Book Description
Reducing health disparities by increasing access to health information is a national health policy priority. Evidence exists that direct-to-consumer pharmaceutical advertising (DTCA) is effective in educating consumers about health issues. However, racial disparities exist in such advertising. In 2009, the Food and Drug Administration (FDA) issued a report that included recommendations for enhancing the ability of DTCA to reach disadvantaged populations, including racial and ethnic minorities. Reducing Race Differences in Direct to Consumer Pharmaceutical Advertising compares the pharmaceutical advertisements placed in five popular women’s magazines published prior to and following the 2009 FDA report to assess the impact of these recommendations on the content and appearance of advertisements placed in magazines of differing racial orientation. From a health policy perspective, the results are disappointing. The FDA recommendations had no impact on the frequency or content of the DTCA appearing in White-oriented versus Black-oriented magazines. In fact, far fewer drugs used to treat life-threatening conditions were advertised in Black-oriented magazines after the 2009 FDA recommendations. The book concludes that enhancing the educational and motivational value of DTCA will require more than a set of recommendations. The results shed light on the pharmaceutical industry’s compliance with both hard and soft regulation. Neither federal recommendations nor industry guidelines resulted in the changes to DTCA envisioned by the FDA. Regulatory action is necessary to ensure that pharmaceutical companies develop advertising campaigns that not only promote their products, but also positively impact the health outcomes of those who read their ads.
Author: Richard B. Ruge
Publisher:
ISBN:
Category :
Languages : en
Pages : 39
Get Book Here
Book Description
Author: United States. Congress. House. Committee on Government Operations
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 25
Get Book Here
Book Description
Author:
Publisher: DIANE Publishing
ISBN: 9781422311578
Category :
Languages : en
Pages : 52
Get Book Here
Book Description
Author: Julie A Fisher
Publisher: CRC Press
ISBN: 9781560243830
Category : Medical
Languages : en
Pages : 180
Get Book Here
Book Description
This important book evaluates trends in pharmaceutical advertising and promotion and addresses many of the perplexing questions involved in assessing drug promotion in our society. It examines legal and ethical issues surrounding pharmaceutical promotions and the benefits of pharmaceutical advertising and promotion and discusses the effectiveness of industry self-regulation and the potential for further legislative or regulatory response. Promotion of Pharmaceuticals offers a framework for understanding the informational effects of pharmaceutical promotion programs from a marketing and economic perspective. It also raises questions regarding pharmaceutical information at the macro level, including: Is pharmaceutical promotion excessive? Are further regulations needed to control the proliferation of misleading messages and to restrict the explicit and implicit persuasive powers of pharmaceutical promotion? What are the implications for the public?s health and social welfare of strict interpretation of the laws regarding dissemination of information on pharmaceuticals?Promotion of Pharmaceuticals suggests a cooperative, not adversarial, relationship between the FDA and the pharmaceutical industry to commit our limited health care resources to facilitating the provision of rational pharmaceutical care. It contains vital information for everyone who wants to make better informed decisions in the complex world of pharmaceuticals. Chapters discuss such relevant topics as regulatory issues for pre- and post-approved drugs, ethical considerations in drug advertising, and FDA and FTC concerns. Promotion of Pharmaceuticals answers questions such as Is pharmaceutical promotion interfering with the doctor-patient relationship? Can good business and good medicine go hand-in-hand? Is the cost of promotion increasing prescription drug prices to an unacceptable level? Other topics include an historical perspective on pharmaceutical advertising and viewpoints from the pharmaceutical leadership. This book is designed for individuals involved in advertising and promotion in the pharmaceutical industry, health care practitioners, consumer advocates, regulators and public policy decision-makers, and other persons involved in the delivery and consumption of pharmaceutical care.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309133947
Category : Medical
Languages : en
Pages : 346
Get Book Here
Book Description
In the wake of publicity and congressional attention to drug safety issues, the Food and Drug Administration (FDA) requested the Institute of Medicine assess the drug safety system. The committee reported that a lack of clear regulatory authority, chronic underfunding, organizational problems, and a scarcity of post-approval data about drugs' risks and benefits have hampered the FDA's ability to evaluate and address the safety of prescription drugs after they have reached the market. Noting that resources and therefore efforts to monitor medications' riskâ€"benefit profiles taper off after approval, The Future of Drug Safety offers a broad set of recommendations to ensure that consideration of safety extends from before product approval through the entire time the product is marketed and used.
Author: United States. Congress. Senate. Special Committee on Aging
Publisher:
ISBN:
Category : Advertising
Languages : en
Pages : 168
Get Book Here
Book Description
